Plasma protein C is a useful clinical marker for hepatic veno-occlusive disease (VOD) in stem cell transplantation

Pediatr Blood Cancer. 2010 Mar;54(3):437-43. doi: 10.1002/pbc.22314.

Abstract

Background: Hepatic veno-occlusive disease (VOD) is one of the most serious complications in stem cell transplantation (SCT). Although plasma protein C activity decreases in VOD after SCT, the timeframe of plasma protein C activity decreases during SCT is not known.

Procedure: We examined levels of plasma protein C serially during the course of SCT to determine the critical level and risk factors for VOD.

Results: Of 151 children who received SCT, 12 of them (7.9%) developed VOD. The mean minimum protein C activity in patients with VOD was significantly lower compared to that in patients without VOD (P < 0.0001). Receiver operating characteristic curve analysis revealed that the critical plasma protein C activity (cut-off point) for VOD was identified to be 34.5% with high sensitivity (100%) and specificity (83.3%), and the reduction of plasma protein C below the cut-off level (day +6.50 +/- 2.43) was observed mostly prior to the onset of VOD (day +7.33 +/- 2.64). The patients receiving melphalan in conditioning were found to be at high risk for VOD (P = 0.003). Among the melphalan containing regimens, melphalan + carboplatin + etoposide was a significant risk factor for depression of plasma protein C (P = 0.037).

Conclusion: Plasma protein C level was a useful parameter of VOD after SCT, and activity below 34.5% was critical for VOD. The use of melphalan in conditioning causes a high risk for VOD.

MeSH terms

  • Adolescent
  • Adult
  • Biomarkers / blood
  • Child
  • Child, Preschool
  • Cholinesterases / blood
  • Female
  • Graft vs Host Disease / enzymology
  • Graft vs Host Disease / prevention & control
  • Hematologic Neoplasms / enzymology
  • Hematologic Neoplasms / therapy
  • Hepatic Veno-Occlusive Disease / enzymology*
  • Hepatic Veno-Occlusive Disease / etiology
  • Hepatic Veno-Occlusive Disease / prevention & control
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Neoplasms / enzymology
  • Neoplasms / therapy
  • Protein C / metabolism*
  • Stem Cell Transplantation / adverse effects*
  • Transplantation Conditioning
  • Young Adult

Substances

  • Biomarkers
  • Protein C
  • Cholinesterases